Normal view MARC view ISBD view

Evolving role of immunotherapy in head-and-neck cancers: A systemic review

In Journal of Head and Neck Physicians and Surgeons
By: Chanana R [Corresponding author].
Contributor(s): Noronha V | Joshi A | Patil V | Prabhash K.
Material type: materialTypeLabelArticlePublisher: 2018Description: .Subject(s): Head-and-neck cancers | Immunology | Immunotherapy | Nivolumab | Pembrolizumab In: Journal of Head and Neck Physicians and Surgeons Vol. 6, no. 1, p.2-11Summary: Head-and-neck squamous cell cancers (HNSCCs) are one of the most common cancers worldwide and account for more than half million new cases and 380,000 deaths per year. A large number of patients are diagnosed with locally advanced disease and require multimodal treatment approaches. Despite advances in radiation and surgical techniques and the use of chemotherapy and monoclonal antibodies in advanced disease, more than half of all patients recur. Tumor cells from various solid malignancies, including HNSCC, over-express PD-LI to habituate the immune checkpoint pathways to evade immune surveillance. In this review, we summarize the current literature on immunotherapeutic options that are available for HNSCC patients.
TMC TMH
Tags from this library: No tags from this library for this title. Add tag(s)
Log in to add tags.
    average rating: 0.0 (0 votes)
Item type Current location Call number Status Date due Barcode
Articles Articles Tata Memorial Hospital
Available AR19057

Address for corresponding author : drraajitchanana@gmail.com

Head-and-neck squamous cell cancers (HNSCCs) are one of the most common cancers worldwide and account for more than half million new cases and 380,000 deaths per year. A large number of patients are diagnosed with locally advanced disease and require multimodal treatment approaches. Despite advances in radiation and surgical techniques and the use of chemotherapy and monoclonal antibodies in advanced disease, more than half of all patients recur. Tumor cells from various solid malignancies, including HNSCC, over-express PD-LI to habituate the immune checkpoint pathways to evade immune surveillance. In this review, we summarize the current literature on immunotherapeutic options that are available for HNSCC patients.

There are no comments for this item.

Log in to your account to post a comment.

Powered by Koha